Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.Georg Pfeiler, Michael Gnant, Robert Königsberg et al.|Journal of Clinical Oncology|2010Cited by 15
Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.Georg Pfeiler, Michael Gnant, Robert Königsberg et al.|Journal of Clinical Oncology|2011Cited by 4
45 Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast CancerRupert Bartsch, G.G. Steger, Zsuzsanna Bagó-Horváth et al.|European Journal of Cancer|2012Cited by 2
Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34P Dubsky, Martin Filipits, Alexander Pichler et al.|Cancer Research|2018Cited by 2
Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 yearsMartin Filipits, Michael Gnant, P Dubsky et al.|Cancer Research|2019Cited by 2